SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is seeing a massive surge in investor sentiment and aggressive upward price action following a blowout earnings report that shattered expectations across all major financial metrics, including a dramatic revenue jump and raised forward guidance. The community is heavily focused on the stock's role as an AI monetization leader, with many celebrating a significant short squeeze while bulls highlight strong institutional support and the company's expanding role in government and enterprise AI.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snap Inc. is trending ahead of its upcoming earnings report, with community members aggressively debating whether the stock is a severely undervalued turnaround play or a long-term liability. The conversation is dominated by speculative sentiment regarding potential ad revenue recovery, the future of its Spectacles hardware, and the possibility of institutional share buybacks or a future acquisition.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is experiencing a relentless upward trend driven by consistent bullish sentiment and aggressive market-maker activity, leading the community to intensely debate whether this parabolic run is a sustainable rally or an unsustainable bubble. While many traders are focused on buying the dip and riding the momentum, others remain skeptical, citing concerns over market manipulation, disconnects from economic fundamentals, and rising hedging activity as the index touches new all-time highs.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending as investors react to the company's latest quarterly report, which highlighted record revenue growth alongside ongoing debate regarding its high cash burn and future financing needs. The community remains divided between long-term supporters focused on recent international approvals and pipeline potential, and skeptics who are increasingly concerned about the lack of specific partnership news and the company's current path toward profitability.

Caterpillar, Inc. engages in the business of manufacturing construction and mining equipment, off-highway diesel and natural gas engines, industrial gas turbines, and diesel-electric locomotives. It operates through the following segments: Construction Industries, Resource Industries, Power and Energy, and All Other. The Construction Industries segment is involved in supporting customers using machinery in infrastructure and building construction applications. The Resource Industries segment offers machinery in mining, heavy construction, quarry, and aggregates. The Power and Energy segment focuses on reciprocating engines, turbines, diesel-electric locomotives, and related services across industries serving oil and gas, power generation, industrial, and transportation applications including marine- and rail-related businesses. The All Other segment includes activities such as the business strategy, product management and development, manufacturing, and sourcing of wear and maintenance components products, parts distribution, integrated logistics solutions, distribution services responsible for dealer development, and administration. The company was founded on April 15, 1925, and is headquartered in Irving, TX.

Caterpillar Inc.

Caterpillar is trending as investors weigh its record-breaking backlog and central role in the AI-driven data center buildout against concerns about a potential bubble in industrial valuations. The community remains divided between long-term holders celebrating the stock's massive year-to-date gains and traders debating whether the industrial giant has become disconnected from traditional cycles.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as shareholders weigh the stock's valuation and high dividend yield against ongoing frustration with stagnant price action and leadership performance despite recent clinical wins. The community remains divided, with some actively accumulating shares for the long-term income while others express deep skepticism regarding the company's growth pipeline and management's effectiveness.

Sterling Infrastructure, Inc. engages in the provision of construction solutions. It operates through the following segments: Transportation Solutions, E-Infrastructure Solutions, and Building Solutions. The Transportation Solutions segment provides infrastructure and rehabilitation services for highways, roads, bridges, airports, ports, light rail systems, water and wastewater facilities, and storm drainage systems. The E-Infrastructure Solutions segment develops advanced, large-scale site development systems and services for data centers, e-commerce distribution centers, warehousing facilities, transportation projects, energy infrastructure, and other specialized developments. The Building Solutions segment provides residential and commercial concrete foundation services for single-family and multi-family homes, as well as parking structures, elevated slabs, and other concrete construction projects. The company was founded in 1955 and is headquartered in The Woodlands, TX.

Sterling Infrastructure Inc

Sterling Construction Company, Inc.

Sterling Infrastructure is trending as investors react to a powerful earnings beat and raised full-year guidance, driven by significant demand in its E-Infrastructure segment for data center construction. The community is actively debating the company's long-term growth potential and recent stock volatility, with many viewing the dips as buying opportunities due to the company's massive project backlog.

Vistra Corp. is a holding company, which engages in the provision of electricity and power generation. It operates through the following segments: Retail, Texas, East, West, and Asset Closure. The Retail segment includes sale of electricity and natural gas to residential, commercial, and industrial customers. The Texas and East segments are involved in electricity generation, wholesale energy sales and purchases, commodity risk management activities, fuel production and fuel logistics management. The West segment represents the company's electricity generation operations in CAISO. The Asset Closure segment refers to the decommissioning and reclamation of retired plants and mines. The company was founded in 1882 and is headquartered in Irving, TX.

Vistra Corp

Vistra Corp is attracting significant investor attention as market sentiment shifts toward the energy infrastructure necessary to support the accelerating power demands of AI and hyperscale data centers. While some market participants express frustration over recent price volatility and technical consolidation, the community remains actively focused on the company's long-term utility-scale potential, institutional accumulation, and its role as a critical power provider in the broader AI buildout.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust (QQQ) is seeing intense community debate driven by renewed geopolitical tensions in the Middle East and concerns over the sustainability of the AI infrastructure sector. Investors are actively trading between optimism for potential tech earnings momentum and apprehension regarding rising bond yields and potential market volatility.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Cipher Digital is surging as investors shift focus toward its role in the AI data center and high-performance computing infrastructure sector, driven by early-than-expected project deliveries and increased hyperscaler demand. Community discussions are heavily centered on the company's long-term pipeline capacity and its strategic transition away from Bitcoin mining, with many investors highlighting the stock's resilience and potential for significant growth as a critical player in power-intensive AI infrastructure.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$ORIC  listened to Jacob Chacko (CEO) at Jefferies and honestly I think many people are missing the most important point.

Rinzimetostat is being developed for metastatic castration-resistant prostate cancer (mCRPC), a lethal disease where, in Chacko’s words, the mortality rate is effectively 100%. The question isn’t if patients die from the disease, but when.

That’s completely different from sickle cell disease, where Fulcrum was operating.

The CEO’s point was simple: FDA doesn’t look at risk in isolation. They look at risk versus benefit. Even if a therapy carries a small risk of secondary malignancy, that risk may be acceptable when treating patients with advanced fatal cancer if the drug meaningfully extends survival.

Andrew

MO OM

StockTwits for iOS

ORIC Pharmaceuticals Inc

  listened to Jacob Chacko (CEO) at Jefferies and honestly I think many people are missing the most important point.

Rinzimetostat is being developed for metastatic castration-resistant prostate cancer (mCRPC), a lethal disease where, in Chacko’s words, the mortality rate is effectively 100%. The question isn’t if patients die from the disease, but when.

That’s completely different from sickle cell disease, where Fulcrum was operating.

The CEO’s point was simple: FDA doesn’t look at risk in isolation. They look at risk versus benefit. Even if a therapy carries a small risk of secondary malignancy, that risk may be acceptable when treating patients with advanced fatal cancer if the drug meaningfully extends survival.

What also stood out was that ORIC has already completed its End-of-Phase 1 meeting with FDA after all the recent PRC2/Tazverik concerns. FDA signed off on the Phase 3 protocol, the dose, and requested no additional prerequisites before starting Himalayas-1.

Not saying risk is zero. But the risk-benefit equation for advanced prostate cancer is very different from sickle cell disease, and I think the market may be treating them as if they’re the same.